Ewing Sarcoma and Neuroectodermal Tumor Biology

Ewing sarcoma is an aggressive paediatric malignancy arising primarily in bone and soft tissue, characterised by specific chromosomal translocations that fuse the EWSR1 gene with ETS family transcription factors, most commonly FLI1. The resulting EWS–FLI1 fusion protein acts as an aberrant transcriptional regulator, rewiring enhancer landscapes and driving oncogenic programmes that promote uncontrolled proliferation, survival and metastatic dissemination. Though genetically simple, these tumours exploit complex epigenetic reorganisation and hijack lineage-specific transcriptional circuits, reflecting a neuroectodermal cell of origin or differentiation programme. Intratumoral heterogeneity arises from dynamic regulation of EWS–FLI1 activity alongside microenvironmental influences such as hypoxia and inflammatory cues. Current standard of care combines multiagent chemotherapy with surgery or radiotherapy, yielding a cure rate of up to 70% for localised disease but remaining dismal for metastatic or recurrent cases. Novel strategies aim to target dependencies created by the fusion oncoprotein, including co-factor interactions, chromatin remodellers and downstream effectors in cell cycle, translation and DNA damage response pathways. Understanding the interplay between oncogenic fusions, epigenetic state and tumour microenvironment is essential for the development of precision therapies and predictive biomarkers in this high-risk tumour family.

Research from Nature Portfolio

Recent studies have uncovered unexpected safeguards and vulnerabilities in the transcriptional circuitry of Ewing sarcoma. One investigation revealed that the homeoprotein SIX1, typically pro-metastatic in other cancers, paradoxically suppresses dissemination in Ewing sarcoma by co-regulating a subset of EWS–FLI1 target genes, including integrins, thereby restraining invasion while still promoting tumour cell growth. Another study identified the ETS factor ETV6 as a critical disease-specific dependency that constrains, rather than reinforces, the transcriptional output of EWS–FLI1. By repressing excessive fusion-driven transcription, ETV6 maintains an optimal oncogenic programme, such that its loss impairs tumour growth. Together, these findings highlight the nuanced balance of co-operative and antagonistic transcription factor interactions that sustain Ewing sarcoma and present new angles for therapeutic intervention.

Ewing Sarcoma and Neuroectodermal Tumor Biology publication trend

The graph below shows the total number of articles in ewing sarcoma and neuroectodermal tumor biology across all publications each year (not limited to Nature Index journals).

Technical terms

EWS–FLI1 fusion protein: Oncogenic chimaera resulting from fusion of EWSR1 and FLI1 genes, functioning as an aberrant transcription factor.
Super-enhancer: Clusters of regulatory elements with high transcription factor occupancy that drive expression of key oncogenes.
Hypoxia-inducible factor (HIF-1α): Master regulator of cellular response to low oxygen, influencing angiogenesis and metabolism.
Extracellular vesicle (EV): Membrane-bound particle secreted by cells, mediating intercellular transfer of proteins and RNAs.
Epigenetic regulation: Modulation of gene expression by chromatin state changes, including histone modifications and DNA methylation.

References

1. Epigenome Mapping Reveals Distinct Modes of Gene Regulation and Widespread Enhancer Reprogramming by the Oncogenic Fusion Protein EWS-FLI1. Cell Reports (2015).
2. Transcriptional Programs Define Intratumoral Heterogeneity of Ewing Sarcoma at Single-Cell Resolution. Cell Reports (2020).
3. Ewing Sarcoma—Diagnosis, Treatment, Clinical Challenges and Future Perspectives. Journal of Clinical Medicine (2021).
4. SIX1 and EWS/FLI1 co-regulate an anti-metastatic gene network in Ewing Sarcoma. Nature Communications (2023).
5. The ETS transcription factor ETV6 constrains the transcriptional activity of EWS–FLI to promote Ewing sarcoma. Nature Cell Biology (2023).
6. Hypoxia and HIFs in Ewing sarcoma: new perspectives on a multi-facetted relationship. Molecular Cancer (2023).
7. Oncogenic ETS fusions promote DNA damage and proinflammatory responses via pericentromeric RNAs in extracellular vesicles. Journal of Clinical Investigation (2024).
8. Epigenetic Control of Translation Checkpoint and Tumor Progression via RUVBL1‐EEF1A1 Axis. Advanced Science (2023).